Gross Profit Summary of Remedent, Inc.

Remedent, Inc.'s latest annual gross profit in 2024 was 603.24 Thousand USD , up 19.32% from previous year.
Remedent, Inc.'s latest quarterly gross profit in 2024 FY was 603.24 Thousand USD , up 19.32% from previous quarter.
Remedent, Inc. reported a annual gross profit of 505.56 Thousand USD in annual gross profit 2023, down -51.71% from previous year.
Remedent, Inc. reported a annual gross profit of 1.04 Million USD in annual gross profit 2022, up 80.96% from previous year.
Remedent, Inc. reported a quarterly gross profit of 603.24 Thousand USD for 2024 FY, up 19.32% from previous quarter.
Remedent, Inc. reported a quarterly gross profit of 117.29 Thousand USD for 2024 Q1, up 3.87% from previous quarter.

Annual Gross Profit Chart of Remedent, Inc. (2024 - 2000)

Historical Annual Gross Profit of Remedent, Inc. (2024 - 2000)

Year	Gross Profit	Gross Profit Growth
2024	603.24 Thousand USD	19.32%
2023	505.56 Thousand USD	-51.71%
2022	1.04 Million USD	80.96%
2021	578.58 Thousand USD	-22.04%
2020	742.17 Thousand USD	-27.2%
2019	1.01 Million USD	-42.79%
2018	1.78 Million USD	50.35%
2017	1.18 Million USD	-39.31%
2016	1.95 Million USD	-16.41%
2015	2.33 Million USD	43.52%
2014	1.62 Million USD	8.23%
2013	1.5 Million USD	-79.84%
2012	7.45 Million USD	-13.6%
2011	8.63 Million USD	119.96%
2010	3.92 Million USD	-51.09%
2009	8.02 Million USD	128.86%
2008	3.5 Million USD	5.18%
2007	3.33 Million USD	-6.92%
2006	3.58 Million USD	-12.43%
2005	4.08 Million USD	44.99%
2004	2.82 Million USD	211.2%
2003	906.46 Thousand USD	290.99%
2002	231.84 Thousand USD	-17.67%
2001	281.6 Thousand USD	-1.91%
2000	287.08 Thousand USD	0.0%

Year	Gross Profit	Gross Profit Growth
2024 Q4	161.61 Thousand USD	-25.39%
2024 FY	603.24 Thousand USD	19.32%
2024 Q1	117.29 Thousand USD	3.87%
2024 Q2	107.74 Thousand USD	-8.15%
2024 Q3	216.59 Thousand USD	101.03%
2023 Q4	112.92 Thousand USD	-24.63%
2023 FY	505.56 Thousand USD	-51.71%
2023 Q3	149.83 Thousand USD	47.75%
2023 Q2	101.4 Thousand USD	-28.28%
2023 Q1	141.39 Thousand USD	0.0%
2022 FY	1.04 Million USD	80.96%
2021 FY	578.58 Thousand USD	-22.04%
2021 Q2	208.85 Thousand USD	36.86%
2021 Q3	209.03 Thousand USD	0.09%
2021 Q1	152.6 Thousand USD	-8.89%
2020 Q4	167.49 Thousand USD	-0.01%
2020 Q3	167.51 Thousand USD	-3.84%
2020 Q2	174.2 Thousand USD	-25.22%
2020 Q1	232.95 Thousand USD	-18.27%
2020 FY	742.17 Thousand USD	-27.2%
2019 Q2	229.1 Thousand USD	-30.43%
2019 Q4	285.03 Thousand USD	4.11%
2019 Q3	273.79 Thousand USD	19.5%
2019 FY	1.01 Million USD	-42.79%
2019 Q1	329.31 Thousand USD	9.26%
2018 Q2	480.99 Thousand USD	4.98%
2018 Q3	541.37 Thousand USD	12.55%
2018 Q4	301.4 Thousand USD	-44.33%
2018 Q1	458.16 Thousand USD	738.2%
2018 FY	1.78 Million USD	50.35%
2017 FY	1.18 Million USD	-39.31%
2017 Q2	403.46 Thousand USD	-5.2%
2017 Q3	427.86 Thousand USD	6.05%
2017 Q4	-71.79 Thousand USD	-116.78%
2017 Q1	425.61 Thousand USD	-1.36%
2016 FY	1.95 Million USD	-16.41%
2016 Q1	561.48 Thousand USD	-4.58%
2016 Q4	431.47 Thousand USD	-7.76%
2016 Q2	491.95 Thousand USD	-12.38%
2016 Q3	467.78 Thousand USD	-4.91%
2015 Q2	614.93 Thousand USD	2.7%
2015 Q4	588.42 Thousand USD	10.23%
2015 Q3	533.82 Thousand USD	-13.19%
2015 Q1	598.76 Thousand USD	1270.08%
2015 FY	2.33 Million USD	43.52%
2014 Q2	512.72 Thousand USD	17.54%
2014 Q3	634.98 Thousand USD	23.84%
2014 FY	1.62 Million USD	8.23%
2014 Q1	436.23 Thousand USD	-45.62%
2014 Q4	43.7 Thousand USD	-93.12%
2013 Q3	367.59 Thousand USD	111.1%
2013 FY	1.5 Million USD	-79.84%
2013 Q4	802.21 Thousand USD	118.23%
2013 Q2	174.13 Thousand USD	8.85%
2013 Q1	159.97 Thousand USD	-83.81%
2012 Q2	2.51 Million USD	15.04%
2012 Q3	1.77 Million USD	-29.44%
2012 Q4	988.31 Thousand USD	-44.27%
2012 FY	7.45 Million USD	-13.6%
2012 Q1	2.18 Million USD	48.94%
2011 Q3	2.33 Million USD	1.28%
2011 FY	8.63 Million USD	119.96%
2011 Q1	2.52 Million USD	65.88%
2011 Q2	2.3 Million USD	-8.52%
2011 Q4	1.46 Million USD	-37.24%
2010 Q2	478.06 Thousand USD	-55.1%
2010 Q4	1.52 Million USD	76.45%
2010 FY	3.92 Million USD	-51.09%
2010 Q1	1.06 Million USD	-38.81%
2010 Q3	861.77 Thousand USD	80.26%
2009 Q3	1.93 Million USD	-2.65%
2009 FY	8.02 Million USD	128.86%
2009 Q4	1.74 Million USD	-9.99%
2009 Q1	2.36 Million USD	41.17%
2009 Q2	1.98 Million USD	-16.08%
2008 Q3	861.52 Thousand USD	211.48%
2008 Q1	579.22 Thousand USD	-46.92%
2008 FY	3.5 Million USD	5.18%
2008 Q4	1.67 Million USD	94.55%
2008 Q2	276.58 Thousand USD	-52.25%
2007 Q4	1.09 Million USD	123.9%
2007 FY	3.33 Million USD	-6.92%
2007 Q3	487.35 Thousand USD	-59.56%
2007 Q2	1.2 Million USD	119.12%
2007 Q1	549.97 Thousand USD	-51.28%
2006 Q4	1.12 Million USD	31.36%
2006 FY	3.58 Million USD	-12.43%
2006 Q1	747.62 Thousand USD	-32.13%
2006 Q2	845.61 Thousand USD	13.11%
2006 Q3	859.37 Thousand USD	1.63%
2005 Q3	1.19 Million USD	42.02%
2005 FY	4.08 Million USD	44.99%
2005 Q2	843.98 Thousand USD	-10.76%
2005 Q1	945.79 Thousand USD	-14.29%
2005 Q4	1.1 Million USD	-8.1%
2004 Q4	1.1 Million USD	11.98%
2004 Q1	391.25 Thousand USD	32.85%
2004 Q2	340.88 Thousand USD	-12.87%
2004 FY	2.82 Million USD	211.2%
2004 Q3	985.35 Thousand USD	189.06%
2003 Q1	216.86 Thousand USD	562.41%
2003 FY	906.46 Thousand USD	290.99%
2003 Q4	294.51 Thousand USD	19.38%
2003 Q3	246.7 Thousand USD	66.27%
2003 Q2	148.37 Thousand USD	-31.58%
2002 Q4	32.73 Thousand USD	-74.45%
2002 FY	231.84 Thousand USD	-17.67%
2002 Q1	8049.00 USD	-63.65%
2002 Q2	62.9 Thousand USD	681.51%
2002 Q3	128.14 Thousand USD	103.72%
2001 FY	281.6 Thousand USD	-1.91%
2001 Q2	14.98 Thousand USD	-88.49%
2001 Q3	93.42 Thousand USD	523.33%
2001 Q4	22.14 Thousand USD	-76.3%
2001 Q1	130.18 Thousand USD	0.0%
2000 FY	287.08 Thousand USD	0.0%

Peer Gross Profit Comparison of Remedent, Inc.

Name	Gross Profit	Gross Profit Difference
American Medical Technologies Inc.	1.69 Million USD	64.497%
Ansell Limited	624.8 Million USD	99.903%
Ansell Limited	624.8 Million USD	99.903%
BG Medicine, Inc.	- USD	-Infinity%
Biotage AB (publ)	113.94 Million USD	99.471%
BioLife Sciences Inc.	- USD	-Infinity%
CB Scientific, Inc.	135.05 Thousand USD	-346.662%
Psykey, Inc.	415.97 Thousand USD	-45.018%
ConvaTec Group Plc	1.2 Billion USD	99.95%
ConvaTec Group Plc	1.17 Billion USD	99.949%
Encision Inc.	3.13 Million USD	80.764%
Golden Valley Development, Inc	- USD	-Infinity%
Hear AtLast Holdings, Inc.	- USD	-Infinity%
Innovative MedTech Inc.	794.01 Thousand USD	24.026%
LifePoint, Inc.	-71.35 Thousand USD	945.371%
Medite Cancer Diagnostics, Inc.	-131 Thousand USD	560.489%
Paradigm Medical Industries, Inc.	525 Thousand USD	-14.903%
QuantRx Biomedical Corporation	- USD	-Infinity%
Reflect Scientific, Inc.	596.42 Thousand USD	-1.143%
SmileDirectClub, Inc.	275.84 Million USD	99.781%
Sector 10, Inc.	- USD	-Infinity%
Shandong Weigao Group Medical Polymer Company Limited	900.72 Million USD	99.933%
SheerVision, Inc.	2.17 Million USD	72.276%
United Health Products, Inc.	-4857.00 USD	12520.012%
Vasamed, Inc.	-69.38 Thousand USD	969.372%
Wearable Health Solutions, Inc.	267.66 Thousand USD	-125.373%
Yubo International Biotech Limited	52.65 Thousand USD	-1045.711%

Global Stocks Search

Remedent, Inc. (REMI)

Gross Profit Summary of Remedent, Inc.

Annual Gross Profit Chart of Remedent, Inc. (2024 - 2000)

Historical Annual Gross Profit of Remedent, Inc. (2024 - 2000)

Peer Gross Profit Comparison of Remedent, Inc.